

UnitedHealthcare Pharmacy
Clinical Pharmacy Programs

Program Number	2024 P 1241-8
Program	Prior Authorization/Notification
Medication	Symdeko® (tezacaftor/ivacaftor)
P&T Approval Date	2/2018, 2/2019, 8/2019, 8/2020, 8/2021, 8/2022, 6/2023, 6/2024
Effective Date	9/1/2024

1. Background:

Symdeko is a combination of tezacaftor and ivacaftor, indicated for the treatment of patients with cystic fibrosis (CF) age 6 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor based on *in vitro* data and/or clinical evidence.

If the patient’s genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of a CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use.

Members will be required to meet the coverage criteria below.

2. Coverage Criteria^a:

A. Initial Authorization

1. **Symdeko** will be approved based on **all** of the following criteria:

a. Diagnosis of cystic fibrosis (CF)

-AND-

b. **One** of the following:

(1) Documentation confirming the patient is homozygous for the F508del mutation in the CFTR gene.

-OR-

(2) Documentation confirming the patient has at least **one** of the following mutations in the CFTR gene that is responsive to Symdeko:

546insCTA	E92K	G576A	L346P	R117G	S589N
711+3A→G*	E116K	G576A;R668 C †	L967S	R117H	S737F
2789+5G→A*	E193K	G622D	L997F	R117L	S912L

3272-26A→G*	E403D	G970D	L1324P	R117P	S945L *
3849+10kbC→T *	E588V	G1069R	L1335P	R170H	S977F *
A120T	E822K	G1244E	L1480P	R258G	S1159 F
A234D	E831X	G1249R	M152V	R334L	S1159 P
A349V	F191V	G1349D	M265R	R334Q	S1251 N
A455E *	F311del	H939R	M952I	R347H *	S1255 P
A554E	F311L	H1054D	M952T	R347L	T338I
A1006E	F508C	H1375P	P5L	R347P	T1036 N
A1067T	F508C;S1251 N †	I148T	P67L *	R352Q *	T1053I
D110E	F508del ‡	I175V	P205S	R352W	V201 M
D110H *	F575Y	I336K	Q98R	R553Q	V232D
D192G	F1016S	I601F	Q237E	R668C	V562I
D443Y	F1052V	I618T	Q237H	R751L	V754 M
D443Y;G576A;R66 8C †	F1074L	I807M	Q359R	R792G	V1153 E

D579G *	F1099L	I980K	Q1291R	R933G	V1240 G
D614G	G126D	I1027T	R31L	R1066H	V1293 G
D836Y	G178E	I1139V	R74Q	R1070Q	W1282 R
D924N	G178R	I1269N	R74W	R1070W *	Y109N
D979V	G194R	I1366N	R74W;D1270N †	R1162L	Y161S
D1152H <u>*</u>	G194V	K1060T	R74W;V201M †	R1283M	Y1014 C
D1270N	G314E	L15P	R74W;V201M;D1270N †	R1283S	Y1032 C
E56K	G551D	L206W *	R75Q	S549N	
E60K	G551S	L320V	R117C *	S549R	

* Clinical data for these mutations in Clinical Studies.

^ A patient must have two copies of the F508del mutation or at least one copy of a responsive mutation presented in the table to be indicated.

† Complex/compound mutations where a single allele of the CFTR gene has multiple mutations; these exist independent of the presence of mutations on the other allele.

Authorization will be issued for 12 months.

B. Reauthorization

1. **Symdeko** will be approved based on the following criterion:

- a. Documentation of positive clinical response to Symdeko therapy (e.g., improved lung function, stable lung function)

Authorization will be issued for 12 months.

^a State mandates may apply. Any federal regulatory requirements and the member specific benefit plan coverage may also impact coverage criteria. Other policies and utilization management

programs may apply.

3. Additional Clinical Rules:

- Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic. Use of automated approval and re-approval processes varies by program and/or therapeutic class.
- Medical Necessity, Supply limits may be in place.

4. References:

1. Symdeko [Package Insert]. Boston, MA: Vertex Pharmaceuticals, Inc.; August 2023.

Program	Prior Authorization/Notification – Symdeko (tezacaftor/ivacaftor)
Change Control	
2/2018	New program
2/2019	Annual review. No changes to coverage criteria. Updated reference.
8/2019	Updated coverage criteria according to label. Updated background and reference.
8/2020	Annual review. No changes to coverage criteria. Updated reference.
8/2021	Annual review. Updated with most recent approved mutation table. Decreased re-authorization to 12 months. Updated reference.
8/2022	Annual review. Removed age criteria. Added state mandate footnote.
6/2023	Simplified reauthorization criteria.
6/2024	Annual review. Updated initial authorization approval duration to 12 months. Updated reference.